Milou Schuurbiers

Ms. Milou Schuurbiers

Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2022 in Chest
Verified
Journal Article
Closed access
SKSharina Kort
Sharina Kort
MBMarjolein Brusse-Keizer
Marjolein Brusse-Keizer
HSHugo Schouwink
Hugo Schouwink
ECEmanuel Citgez
Emanuel Citgez
FJFrans H. de Jongh
Frans H. de Jongh
JPJob van der Palen
Job van der Palen

27 June 2022 in Molecular Oncology
Verified
Journal Article
Open access
DVDaan Vessies
Daan Vessies
MSMilou Schuurbiers
Milou Schuurbiers
VNVincent van der Noort
Vincent van der Noort
ISIrene Schouten
Irene Schouten
TLTheodora C. Linders
Theodora C. Linders
DBDaan van Den Broek
Daan van Den Broek
Stage II–IIIA nonsmall cell lung cancer (NSCLC) patients receive adjuvant chemotherapy after surgery as standard‐of‐care treatment, even though only approximately 5.8% of patients will benefit. Identifying patients with minimal residual disease (MRD) after surgery using tissue‐informed testing of postoperative plasma circulating cell‐free tumour DNA (ctDNA) may allow adjuvant therapy to be withheld from patients without MRD. However, the detection of MRD in the postoperative setting is challenging, and more sensitive methods are urgently needed. We developed a method that combines variant calling and a novel ctDNA fragment length analysis using hybrid capture sequencing data. Among 36 stage II–IIIA NSCLC patients, this method distinguished patients with and without recurrence of disease in a 20 times repeated 10‐fold cross validation with 75% accuracy (P = 0.0029). In contrast, using only variant calling or only fragment length analysis, no signification distinction between patients was shown (P = 0.24 and P = 0.074 respectively). In addition, a variant‐level fragmentation score was developed that was able to classify variants detected in plasma cfDNA into tumour‐derived or white‐blood‐cell‐derived variants with 84% accuracy. The findings in this study may help drive the integration of various types of information from the same data, eventually leading to cheaper and more sensitive techniques to be used in this challenging clinical setting.

15 April 2025 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
MSMilou Schuurbiers
Milou Schuurbiers
CSChristopher G. Smith
Christopher G. Smith
KHKoen J. Hartemink
Koen J. Hartemink
RRRobert C. Rintoul
Robert C. Rintoul
DGDavina Gale
Davina Gale
OGOn Behalf of the LEMA Study Group and the LUCID Study Group
On Behalf of the LEMA Study Group and the LUCID Study Group
Background: Despite treatment with curative intent, many patients with localized non-small cell lung cancer (NSCLC) develop recurrence. The current challenge is to identify high-risk patients to guide adjuvant treatment. Identification of residual disease by detection of circulating tumor DNA (ctDNA) may allow more accurate clinical decision-making, but its reliability in NSCLC is not established. We aimed to build on previous data to validate a tissue-informed personalized ctDNA assay, to predict recurrence in patients with early-stage disease. Methods and findings: Tumor tissue and plasma was collected from patients with stage 0–III NSCLC enrolled to LEMA (Lung cancer Early Molecular Assessment trial, NCT02894853). Serial plasma was collected before and after definitive treatment, with the latter including key timeframes of interest (1–3 days post-treatment, between 14 and 122 days after treatment end, and ≥14 days after treatment end). Somatic mutations identified by tumor exome sequencing were used to design patient-specific assays, to analyze ctDNA. Results were compared and combined with an independent dataset (LUCID; LUng Cancer CIrculating Tumour Dna study, NCT04153526). In LEMA, 130 patients (57% male; median age 66 years (range 44–82); 69% adenocarcinoma, 22% squamous cell carcinoma (SCC); 3%/49%/19%/29% with stage 0/I/II/III) were treated with curative intent. Tumor tissue originated from surgical resection or diagnostic biopsy in 118 and 12 patients respectively. LUCID included 88 patients (51% male; median age 72 years (range 44–88); 63% adenocarcinoma, 31% SCC; 49%/28%/23% with stage I/II/III). Before treatment, ctDNA was detected in 48% LEMA and 51% LUCID patients. Sensitivity, specificity, positive and negative predictive value of ctDNA detection post-treatment (≥1 positive sample ≥14 days after treatment end) to predict recurrence were 61%, 97%, 92% and 84% for LEMA and 64%, 96%, 90% and 83% for LUCID. In the combined cohort, ctDNA detection after treatment was associated with shorter recurrence-free survival (hazard ratio (HR) 11.4 (95% confidence interval (CI) [7.0,18.7]; p < 0.001)) and overall survival (HR 8.1 (95% CI [4.6,14.2]; p < 0.001)), accounting for guarantee-time bias. Of note, a key limitation of this work was the irregular sample collection schedules, during routine follow-up visits, of both studies. Conclusions: ctDNA detection predicted recurrence in independent retrospective cohorts with notable reproducibility, including near-identical detection rates and predictive values, confirming its ability to differentiate patients at high- versus low risk of recurrence. Our results support the potential of tissue-informed ctDNA analysis as a decision-support tool for adjuvant therapy in NSCLC.

25 February 2022 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
MSMilou Schuurbiers
Milou Schuurbiers
ZHZhongyun Huang
Zhongyun Huang
SSSenglor Saelee
Senglor Saelee
MJManana Javey
Manana Javey
LVLeonie de Visser
Leonie de Visser
DKDaniel Klass
Daniel Klass
Background Patients treated with immunotherapy are at risk of considerable adverse events, and the ongoing struggle is to accurately identify the subset of patients who will benefit. Tumor mutational burden (TMB) has emerged as a promising predictive biomarker but requires tumor tissue which is not always available. Blood-based TMB (bTMB) may provide a minimally invasive assessment of mutational load. However, because of the required sequencing depth, bTMB analysis is costly and prone to false negative results. This study attempted to design a minimally sized bTMB panel, examined a counting-based method for bTMB in patients with stage I to IV non-small cell lung cancer (NSCLC) and evaluated both technical factors such as bTMB and tissue-based TMB (tTMB) cut-off, as well as sample-related factors such as cell-free DNA input mass which influence the correlation between bTMB and tTMB. Methods Tissue, plasma, and whole blood samples collected as part of the LEMA trial (NCT02894853) were used in this study. Samples of 185 treatment naïve patients with stage I to IV NSCLC were sequenced at the Roche Sequencing Solutions with a custom panel designed for TMB, using reagents and workflows derived from the AVENIO Tumor Tissue and circulating tumor DNA Analysis Kits. Results A TMB panel of 1.1 Mb demonstrated highly accurate TMB high calls with a positive predictive value of 95% when using a tTMB cut-off of 16 mut/Mb, corresponding with 42 mut/Mb for bTMB. The positive per cent agreement (PPA) of bTMB was relatively low at 32%. In stage IV samples with at least 20 ng of cfDNA input, PPA of bTMB improved to 63% and minimizing the panel to a subset of 577 kb was possible while maintaining 63% PPA. Conclusion Plasma samples with high bTMB values are highly correspondent with tTMB, whereas bTMB low results may also be the result of low tumor burden at earlier stages of disease as well as poorly shedding tumors. For advanced stages of disease, PPA (sensitivity) of bTMB is satisfactory in comparison to tTMB, even when using a panel of less than 600 kb, warranting consideration of bTMB as a predictive biomarker for patients with NSCLC eligible for immunotherapy in the future.

4 October 2022 in Heliyon
Verified
Journal Article
Open access
FDFrederik van Delft
Frederik van Delft
MSMilou Schuurbiers
Milou Schuurbiers
MMMirte Muller
Mirte Muller
SBSjaak A. Burgers
Sjaak A. Burgers
HRHuub H. van Rossum
Huub H. van Rossum
MHMichel van den Heuvel
Michel van den Heuvel
Serum tumor markers acquired through a blood draw are known to reflect tumor activity. Their non-invasive nature allows for more frequent testing compared to traditional imaging methods used for response evaluations. Our study aims to compare nine prediction methods to accurately, and with a low false positive rate, predict progressive disease despite treatment (i.e. non-response) using longitudinal tumor biomarker data. Bi-weekly measurements of CYFRA, CA-125, CEA, NSE, and SCC were available from a cohort of 412 advanced stage non-small cell lung cancer (NSCLC) patients treated up to two years with immune checkpoint inhibitors. Serum tumor marker measurements from the first six weeks after treatment initiation were used to predict treatment response at 6 months. Nine models with varying complexity were evaluated in this study, showing how longitudinal biomarker data can be used to predict non-response to immunotherapy in NSCLC patients.

17 March 2025 in Tumor Biology
Verified
Journal Article
Open access
MSMilou Schuurbiers
Milou Schuurbiers
FDFreek A. van Delft
Freek A. van Delft
HKHendrik Koffijberg
Hendrik Koffijberg
MIMaarten J. Ijzerman
Maarten J. Ijzerman
KMKim Monkhorst
Kim Monkhorst
MHMichel M. van Den Heuvel
Michel M. van Den Heuvel
Background: Immune checkpoint inhibitors (ICIs) provide a significant survival benefit in non-small cell lung cancer (NSCLC) patients; however, accurately predicting which patients will benefit remains a challenge. As previously shown, the STOP model, a machine learning model based on serum tumor markers, is capable of identifying non-responders after 6 weeks of ICIs. Objective: This study aims to externally validate this model and to assess the predictive value in combination with radiological response assessment using RECIST criteria. Methods: In a cohort of 242 metastatic NSCLC patients, CYFRA, CEA, and NSE were measured before start and after 6 weeks of ICI treatment. The ability of the STOP model to predict no durable benefit (NDB; progressive disease, death within 6 months or disease control of less than 6 months) was assessed using specificity and positive predictive value (PPV). Moreover, a combination of the STOP model with RECIST after 6–8 weeks of ICIs was investigated. Results: The STOP model achieved a specificity of 96% (95% CI 95%–97%) and a PPV of predicting NDB of 88.1% (95% CI 85.9%–90.3%). Combining the STOP model with RECIST improved specificity and PPV to 100% and predicted NDB on average 11.6 weeks (IQR 1.8–18.0 weeks) prior to developing radiologically defined progression. Conclusions: After 6 weeks of ICIs, the blood-based STOP model was capable of accurately predicting NDB in metastatic NSCLC patients, earlier than conventional radiological assessment. The combined serological and radiological response assessment creates an early opportunity to safely stop ICI treatment in patients who will not benefit, although the clinical utility of the assay is limited since the high specificity comes at the cost of a lower sensitivity.